s0094283
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.300
- ANGIOGENESIS+0.200
- APICAL_SURFACE+0.200
- KRAS_SIGNALING_DN+0.200
- MYOGENESIS+0.200
- PANCREAS_BETA_CELLS+0.200
- COAGULATION+0.100
- ESTROGEN_RESPONSE_EARLY+0.100
- ESTROGEN_RESPONSE_LATE+0.100
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.100
Top 10 suppressed
- E2F_TARGETS-0.500
- G2M_CHECKPOINT-0.500
- MITOTIC_SPINDLE-0.500
- TGF_BETA_SIGNALING-0.500
- INTERFERON_ALPHA_RESPONSE-0.400
- INTERFERON_GAMMA_RESPONSE-0.400
- MYC_TARGETS_V1-0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.300
- IL6_JAK_STAT3_SIGNALING-0.300
- MTORC1_SIGNALING-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-NJ-A4YF-01A-12R-A262-07 | — | cohortA3 | 0.870 |
| 2 | SRR25617874 | — | B | 0.846 |
| 3 | TCGA-62-A46P-01A-11R-A24H-07 | — | cohortA3 | 0.843 |
| 4 | SRR1085825 | GTEX | — | 0.838 |
| 5 | SRR1440058 | GTEX | — | 0.832 |
| 6 | MNG543 | — | — | 0.831 |
| 7 | SRR1349013 | GTEX | — | 0.826 |
| 8 | TCGA-CV-6937-01A-11R-2016-07 | — | — | 0.826 |
| 9 | SRR1341763 | GTEX | — | 0.821 |
| 10 | SRR25617843 | — | B | 0.820 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| COAGULATION | 0.100 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.100 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.100 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |